RenovoRx, Inc. Common Stock (RNXT) is a publicly traded Healthcare sector company. As of November 5, 2026, RNXT trades at $1.15 with a market cap of $59.12M and a P/E ratio of -5.14. RNXT moved -8.78% today. Year to date, RNXT is +25.79%; over the trailing twelve months it is +16.02%. Its 52-week range spans $0.70 to $2.59. Analyst consensus is strong buy with an average price target of $7.13. Rallies surfaces RNXT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
RenovoRx Q3 2026 net loss widens 25% year over year to $3.65 million: RenovoRx reported a third-quarter 2026 net loss of $3.65 million, up 25% year over year, as revenue rose to $1.07 million. Full-year revenue guidance remained $3.75 million to $4.25 million.
| Metric | Value |
|---|---|
| Price | $1.15 |
| Market Cap | $59.12M |
| P/E Ratio | -5.14 |
| EPS | $-0.31 |
| Dividend Yield | 0.00% |
| 52-Week High | $2.59 |
| 52-Week Low | $0.70 |
| Volume | 331.90K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.22M |
| Net Income | $-12.29M |
| Gross Margin | 75.07% |
4 analysts cover RNXT: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.13.